Annette North - 09 Feb 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Role
EVP & General Counsel
Signature
/s/ Paolo Tombesi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Feb 2022
Net transactions value
-$24,285
Form type
4
Filing time
11 Feb 2022, 17:09:14 UTC
Previous filing
31 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TPTX Common Stock Sale $24,285 -669 -5.4% $36.30 11,696 09 Feb 2022 Direct F1
transaction TPTX Common Stock Award $0 +16,283 +139% $0.000000 27,979 09 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Award $0 +58,600 $0.000000 58,600 09 Feb 2022 Common Stock 58,600 $37.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
F2 Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
F3 1/48th of the shares vest monthly following February 9, 2022.